Home Tags Prescription Drugs

Tag: Prescription Drugs

For individuals with heart failure

Meds Taken Do Not Vary With ADL Impairment in Heart Failure

Adults with heart failure with impairment in activities of daily living take as many meds as those without
Tamoxifen at a dose of 5 mg/day is associated with a reduced risk for recurrence for women with hormone-sensitive breast intraepithelial neoplasia

SABCS: Low-Dose Tamoxifen Cuts Risk for Breast Dz

More second primary cancers and more frequent menopausal symptoms seen in tamoxifen vs. placebo arm
For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab

SABCS: T-DM1 Cuts Recurrent Invasive HER2+ Breast CA Risk

Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo
For patients with CD30-positive peripheral T-cell lymphoma

ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma

Median progression-free survival improved with A+CHP vs CHOP; similar incidence of adverse events
A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears in the lining of the arteries in the head and neck

FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug

Alemtuzumab label will be updated to include the risk for stroke and arterial dissection
For older patients with untreated chronic lymphocytic leukemia

ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL

Improved progression-free survival with ibrutinib for older adults with untreated CLL
Certain sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk in patients with type 2 diabetes and atherosclerotic cardiovascular disease

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
For patients with hereditary angioedema type I or II

Lanadelumab Reduces Attack Rate in Hereditary Angioedema

Significant reduction in attack rate compared with placebo seen for three dose regimens of lanadelumab
Participation in the Supplemental Nutrition Assistance Program may reduce the number of low-income older adults with diabetes forgoing medications because of cost

Food Assistance May Help Older Adults Adhere to Diabetes Meds

Food assistance may cut number of older adults with diabetes forgoing medications due to cost
For older adults with dementia

Risks of Trazodone Similar to Those of Atypical Antipsychotics

Among older adults with dementia, rates of falls, fracture similar, but mortality rate lower